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Background: S. pneumoniae is a major cause of meningitis, pneumonia and sepsis in children. In 2006 universal
pneumococcal vaccination was recommended in Germany for all children up to their second birthday. We have
compared the prevalence and outcome of IPD at a single hospital before and after the introduction of vaccination.
Findings: 55 cases of IPD were identified over an 11 year period. Almost half of the patients were younger than
2 years of age. Most of the children were affected by pneumonia. The second highest incidence seen was for
meningitis and sepsis. 17 patients exhibited additional complications. Significant pre-existing and predisposing
disorders, such as IRAK 4 defect, ALPS or SLE were identified in 4 patients. Complete recovery was seen in 78% of
affected children; 11% had a fatal outcome and 11% suffered from long term complications. Only 31% overall had
been vaccinated. The most common serotype was 14. Serotypes not covered by any of the current vaccines were
also found. Antibiotic treatment commenced with cephalosporins in over 90%.
Conclusion: Frequency of IPD in our hospital did not decrease after initiation of the pneumococcal vaccination.
This might be due to vaccinations not being administered satisfactorily as well as to poor education about the
need of the vaccination. Pre-existing diseases must be monitored and treated accordingly and rare deficiencies
taken into account when IPD takes a foudroyant course. In addition, antibiotic stewardship has been initiated at
this hospital centre as a consequence of the high cephalosporin use detected in this study.
Keywords: Streptococcus pneumoniae, Invasive pneumococcal disease (IPD), Complications, Children, Serotypes,
Pneumococcal vaccinationFindings
Background
Pneumococci are one of the major causes of meningitis,
pneumonia and sepsis in children [1-3] and such invasive
pneumococcal disease (IPD) is a leading cause of death
and significant morbidity in young children in developed
countries, particularly those under the age of two [4,5].
The occurrence of distinct serotypes differs with clinical
presentation, age and geographical region [6-10]. Since the
1980s a 23-valent polysaccharide vaccine (PPV23) has
been available for adults and children older than two
years, because of its poor immunogenicity in younger age
groups. The pneumococcal conjugate vaccine 7 (PCV 7),* Correspondence: Wieland.Kiess@medizin.uni-leipzig.de
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distribution, and reproduction in any mediumwhich covers the most important seven serotypes causing
IPD in children (4, 6B, 9 V, 14, 18C, 19 F, and 23 F) was
additionally licensed by the European Union in 2001
[11-14]. In Germany the pneumococcal vaccination has
been recommended since July 2006 by the German
Standing Vaccination Committee (STIKO) at the Robert
Koch Institute for all children up to their second birthday.
Three years later, in 2009, PCV 10 which covers three more
serotypes (1, 5, 7 F) and PCV 13 for additional coverage of
serotypes 3, 6A and 19A were introduced and approved for
use in Europe [9,15]. Following the introduction of this vac-
cination scheme the frequency of IPD with vaccine sero-
types has decreased but the number of non-vaccine cases is
slowly increasing, suggesting the need for wider serotype
coverage in future PCV vaccines [9,11,14,16]. A successful
vaccination programme will not only lead to a reduction in
the incidence of pneumococcal diseases but will also result
in decreased utilisation of antibiotics, thus preserving theirntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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opment of antibiotic resistance, especially the resistance to
penicillin, β-lactams and macrolides, which has steadily be-
come more prevalent worldwide over the last 30 years
[1,11,17,18].
Based on the information above and focusing on a single
hospital centre (the Hospital for Children and Adoles-
cents, Department of Woman and Child Health, Leipzig,
Germany) we have asked:
What is the prevalence of IPD at one hospital centre?
What are the outcomes from the disease?
What co morbidities were present and what disease
complications resulted?
Which antibiotic treatments were used?
Which serotypes were prevalent?




This retrospective study includes all patients up to
18 years of age treated as an inpatient for IPD between
1st January 2001 and 31st December 2011. A diagnosis of
IPD was defined as isolation of S. pneumoniae from
blood, cerebrospinal fluid or pleural puncture cultures,
but also by tracheal aspirate which was obtained from
some of the paediatric patients requiring tracheal tubes
and assisted ventilation.
These definitions corresponded with ICD numbers
A40.3 (sepsis due to S. pneumoniae), G00.1 (pneumococ-
cal meningitis) or J13 (pneumonia due to S. pneumoniae).
Age
Patients were assigned to one of three age groups to aid
further analysis: patients younger than two, patients of
two to four years of age, and patients of five to 18 years
of age.
Acute disease complications and pre-existing conditions
Acute complications of IPD e.g. Waterhouse Friderichsen
Syndrome (WFS), haemolytic uremic syndrome (HUS) or
disseminated intravascular coagulation (DIC), were rou-
tinely assessed for. All incidences of hydrocephalus, sei-
zures, oculomotor palsy and deafness were also assessed.
Pre-existing conditions such as unrelated chronic dis-
ease, immunodeficiency or other systemic diseases were
evaluated.
Vaccination
We assessed whether pneumococcal vaccination had
taken place and if the immunisation program was com-
pleted by the onset of IPD. Since universal pneumococ-
cal vaccination was only routinely recommended in July
2006, the patients were split into two groups for furtheranalysis, those being treated between 2001 and 2006,
and those being treated between 2006 and 2011.
Serotypes
Serotypes were derived from patient records held at the
institute of microbiology, University of Leipzig. Additional
serotype information was obtained from Dr Mark van
der Linden (National Reference Centre for Streptococci,
Department of Medical Microbiology and University Hos-
pital RWTH Aachen).
Antibiotic treatment and resistance
Initial, empirical therapy was recorded, as well as any
subsequent alteration to antibiotic treatment. Data on
antibiotic resistance was also recorded.
Outcome
Outcome measures were grouped as follows: complete
recovery, significant complications and death.
Statistical analysis
Standardised data was recorded in a relational database
and descriptive statistics performed utilising SPSS for
Windows version 17 (SPSS Inc., Chicago, Illinois, USA).
Ethical statement
Ethical approval of this retrospective case study was ob-
tained from the clinical ethical committee of the Chil-
dren´s hospital of the University of Leipzig and data
protection committee approval has been given by the in-
ternal review board of the hospital as well.
Results
Demographics
Between 1st January 2001 and 31st December 2011, a total
of 55 cases of IPD were detected in children and adoles-
cents aged between 0 and 18 years in a single centre. The
frequency of cases between 2001 and 2006 was on average
four per year and from 2006 to 2011 five per year. Of the
55 patients diagnosed with IPD, 84% (n = 46) had a posi-
tive culture and in 16% (n = 9) the diagnosis was made
based on a positive urinary pneumococcal antigen test. In
11% (n = 6) of the cases the diagnosis was based on
tracheal secretion cultures (n = 3 in 2005, (n = 2 in 2006,
n = 1 in 2011).
The median age was 30 months with a minimum age
of one month and a maximum of 17 years. 47% of all
cases were younger than two years, 29% between the age
of two to four years and 24% older than five years. A
total of 76% were therefore younger than five years
(n = 18 from 2001 to 2006, n = 24 from 2006 to 2011).
34 patients (62%) were male and 21 patients (38%)
female.
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A total of 24 children (44%) were affected by pneumonia
and nine (38%) of those had pneumonia with effusion
(Figure 1a). Eleven patients (20%) suffered from purulent
meningitis of which two children (18%) had a subdural
effusion (Figure 1b). Sepsis due to S. pneumoniae wasFigure 1 Radiological findings in three patients with invasive
pneumococcal disease. a: Chest X-ray: Widespread, significant
opacification of left hemithorax representing lobar pneumonia with
effusion secondary to S. pneumoniae in a six year old girl. b:
Coronary T1-weighted MRI after contrast agent injection: Subdural
hygroma in the left hemisphere and increased meningeal
enhancement in a one year old boy diagnosed with meningitis
secondary to S. pneumoniae. c: T2-weighted MRI without contrast
agent: Internal hydrocephalus and pronounced necrosis of the
cerebral parenchyma (left > right) in a one month old girl, secondary
to IPD with fatal outcome.identified in nine cases (16%). Six children (11%) were
diagnosed with pneumonia and sepsis at the same time
(50% pneumonia with effusion, n = 3) and five patients
(9%) with meningitis and sepsis (Figure 2).Complications
Thirteen patients (24%) had acute disease complications.
One patient (2%) was diagnosed with haemolytic uremic
syndrome (HUS), two patients (4%) with disseminated
intravascular coagulation (DIC) and another two children
(4%) suffered from HUS and DIC concurrently. Four pa-
tients (7%) suffered a seizure and three (6%) a seizure as
well as DIC. One oculomotor palsy (2%) and an occlusive
hydrocephalus with pronounced necrosis of the cerebral
parenchyma (Figure 1c) combined with DIC (2%) were
also detected. In the patients evaluated no diagnoses of
Waterhouse Friderichson Syndrome (WFS) or deafness
were found.Pre-existing disease
In 12 patients significant pre-existing diseases were
present. Two siblings were diagnosed with meningitis and
sepsis due to S. pneumoniae, resulting in similar disease
courses with a fatal outcome. The possibility of immuno-
deficiency was therefore considered and the children were
subsequently demonstrated to be homozygous for an
interleukin-1 receptor-associated kinase 4 (IRAK 4) defi-
ciency. Another patient was known to have pre-existing
autoimmune lymphoproliferative syndrome (ALPS) and
went on to make an unremarkable recovery. One further
patient had pre-existing systemic lupus erythematosus
(SLE) which led to a foudroyant course with fatal outcome.Recovery
Complete recovery was recorded in 43 patients (78%); six
children (11%) died and another six (11%) suffered from
long-term complications. Most fatalities were found in
those under the age of two years (n = 4); whereas only two
fatal outcomes were detected in the age group between
five and 18 years. The highest numbers of long-term com-
plications were identified within the age group two to four
years (n = 3), followed by the < two years (n = 2) and the
five to 18 years (n = 1). Three patients suffered from renal
failure due to haemolytic uremic syndrome (HUS). One
15 month old child received an allogeneic renal trans-
plantation. One patient with oculomotor palsy secondary
to meningitis had a persistent ptosis as well as a gaze par-
esis. Another child with meningitis and effusion suffered
from a right-sided hemiparesis and hyperkinesis, as well as
an intention tremor. The relation between pre-existing
diseases as well as acute and long-term complications is
shown in Table 1.
Figure 2 Clinical presentation of invasive pneumococcal disease in 55 children at the Hospital for Children and Adolescents,
Department for Women and Child Health, University of Leipzig, Germany from 2001 to 2011.
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In total 17 patients (31%) had previously been vacci-
nated, 15 (88%) of them between 2006 and 2011 when
universal pneumococcal vaccination was generally rec-
ommended. Only nine of the 17 vaccinated patients had
received the full immunisation of four doses of vaccine
before onset of the disease. Despite full vaccination one
sibling with IRAK 4 deficiency died. Thirteen children
(77%) completely recovered. Three patients (18%) with-
out completed vaccination courses suffered from long-Table 1 Table demonstrating further information on children
(12 out of 55)
Age (month) IPD Pre-existing disease Acute c
1 Sepsis None DIC + h
7 Meningitis + sepsis IRAK-4-deficiency DIC +
14 Meningitis None Con
15 Pneumonia + sepsis None
18 Pneumonia + sepsis None
18 Meningitis None DIC +
37 Meningitis with effusion None oculom
39 Meningitis None
53 Pneumonia None
64 Meningitis + sepsis IRAK-4-deficiency DIC +
79 Pneumonia with effusion ALPS
156 Pneumonia + sepsis SLE
*Within 2 weeks after onset of disease.
**4 or more weeks after onset of disease.term complications and in these patients we could only
identify three serotypes (3, 12 F and 19A). Serotype 12 F
is to date not part of any pneumococcal vaccination for
children less than two years. Serotypes 3 and 19A are
part of PCV 13 but not PCV 7. At the time of diagnosis
of those two IPD cases, PCV 7 was the vaccine in gen-
eral utilisation and therefore did not cover serotype 3
and 19A.
Of 55 cases 21 serotypes were identified; the most fre-
quent one was serotype 14 (n = 5, 9%; Table 2).that developed acute or long-term complications or died




HUS End stage renal disease (ESRD)
HUS Chronic renal failure
convulsive fit Death
otorius palsy Ptosis, gaze paresis
None Right-sided hemiparesis, hyperkinesis + intention tremor
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In 51 cases (93%) initial antimicrobial therapy was per-
formed with cephalosporins (cefuroxime n = 30, 59%;
cefotaxime n = 18, 35%; ceftazidime n = 3, 6%). In the
remaining cases initial antibiotic treatment (each n = 1,
2%) was carbapenems or glycopeptides (vancomycin)
and in two patients (4%) aminopenicillins (ampicillin). In
15 cases (27%) a change of therapy was deemed neces-
sary based on culture results or microbiological advice,
often leading to combined antibiotic regimen (n = 5, 9%)
or a switch to carbapenems (n = 7, 13%). In two patients
treatment was changed to a cephalosporin of a higher
group and in another patient to a lincosamide antibiotic.
Microbiological findings revealed antibiotic resistance in
10 patients (18%), half of which demonstrated resistance
to polymyxins and in two cases (4%) to macrolides. The
rate of resistance to lincosamides, ketolides, aminogly-
cosides, aminopenicillins and second generation ce-
phalosporins was less than 3%. Intermediate resistance
was identified in 11 cases (20%); six patients (11%) for
second-generation fluoroquinolones, four patients (7%)
to macrolides and one (2%) to penicillin.
Discussion and conclusion
The incidence of IPD in this single hospital centre has
not significantly changed since the introduction of the
general vaccination programme in 2006. It seems that
more IPD cases were diagnosed between 2006 and 2011
than in the pre-vaccination era between 2001 and 2006,
with a maximum of 11 cases in 2011. Even though stud-
ies overall show that IPD has decreased [4,16] why have
the diagnoses of IPD increased in this single centre?
Looking critically into possible reasons, one theory to
explain the high number of IPDs detected between 2006
and 2011 could be the use of new diagnostic methods
after 2006 such as the urinary antigen test. Nine of the
11 cases in 2011 were found to be diagnosed with this
test rather than by culturing of S.pneumomiae. In con-
trast to this theory, this test has a high sensitivity but
quite poor specificity, potentially resulting in false-
positive results which may drive up the number of diag-
noses and distort the true number of IPD detections
[19,20]. Increased attention to the disease and a subse-
quent higher rate of blood-cultures could also lead to
this apparent increase in diagnoses [16,21]. Furthermore,
another important reason could be the low frequency ofTable 2 Pneumococcal serotypes and their frequencies in 21
Serotype 3 6A 6B 7 F 9 N 1
Frequency 2 1 2 2 1
Coveredby PCV-7 no no yes no no n
Coveredby PCV-13 yes yes yes yes no y
Vaccinated n = 1 n = 0 n = 0 n = 0 n = 0 nvaccinations: only 17 (33%) of the total 55 patients had
been vaccinated. In most European countries pneumo-
coccal vaccination with PCV7 was recommended since
2006. Most of the countries report a decrease of vaccine
serotypes but higher numbers of non-vaccine serotypes
were also noticed [22]. The serotypes (6B, 14, 18C, 23 F)
identified in nine of the children in the pre-vaccination
era could have been mainly covered by PCV 7 which un-
derlines the need of the introduction of pneumococcal
vaccination in that time. A similar situation was seen be-
tween 2006 and 2011. In six cases the identified sero-
types (3, 6A, 7 F, 19A) would have been covered by PCV
13 but the children were suffering from IPD before
2009. This was therefore before the introduction of PCV
13 which might have prevented the disease. On the
other hand in four patients during 2001 and 2011 the se-
rotypes 10A, 12 F, 34 and 9 N were identified which are
to date not part of any pneumococcal vaccination for
children under two years of age.
Serotype 14 is one of the most common serotypes in
Europe in children under 18 years of age [4,8,23,24] and
was also present in five patients in our study. Kaplan
et al. state that serotype 19A is currently the most com-
mon serotype in the United States after PCV7 introduc-
tion [25]. In Germany a higher incidence of IPD caused
by serotype 19A was also noticed in 2008/2009 whereas
19A isolates remained below 5% before 2006. The cause
for this might be due to increased reporting after intro-
duction of PCV7, but an increased use of cephalosporins
is also a possibility for the change in 19A epidemiology
[22]. In our hospital two cases were identified in 2008.
Both children were vaccinated with PCV7 which does
not cover serotype 19A. Overall 93% of the children
were treated with cephalosporins. Data regarding anti-
biotic use in Germany show a significant increase in
cephalosporin use which may have led to an increase of
serotype 19A [22].
Pre-existing diseases especially immunodeficiencies
and autoimmune diseases may increase the risk of IPD.
The ALPS found in one of the children usually develops
in early childhood and is an autoimmune condition
caused by an inherited defect in the immune system sec-
ondary to an error in the Fas or FasL gene. The Fas gene
normally functions to induce lymphocyte apoptosis and
such defects reduce cell death among lymphocytes after
infection, leading to a higher number of lymphocytespatients with IPD in a single hospital centre
0A 12 F 14 18C 19A 19 F 23 F 34
1 1 5 1 2 1 1 1
o yes yes no no no yes no
es yes yes yes yes yes yes no
= 0 n = 1 n = 0 n = 0 n = 2 n = 0 n = 0 n = 0
Schnappauf et al. BMC Research Notes 2014, 7:145 Page 6 of 7
http://www.biomedcentral.com/1756-0500/7/145that continue to create antibodies [26]. Patients with
ALPS should receive all childhood vaccinations includ-
ing pneumococcal vaccination to reduce the number of
potential infections. The child in this study did not re-
ceive pneumococcal vaccination due to suffering from
IPD one year before the vaccination in Germany was
generally recommended. In this instance ALPS was only
diagnosed when the child was already suffering from
IPD and therefore no preventative, early immunisations
had been administered.
One patient was known to have SLE, which can in-
crease the risk and frequency of S. pneumoniae infec-
tions due to significantly reduced opsonisation of S.
pneumoniae with C3b/iC3b in serum [27-29]. Besides
SLE itself being a systemic autoimmune disease which
can affect any part of the body, it leads to multisystem
organ failure and death [27-29] as it was also shown in
our patient who died of pneumococcal pneumonia and
sepsis after 6 days of hospital treatment at the age of
13 years.
Two siblings were affected by IRAK-4 deficiency, a rare
primary immunodeficiency with severe impairment of Toll-
like receptor (TLR) and interleukin-1 receptor-mediated
immunity [30-33]. Patients with IRAK-4 deficiency are
highly susceptible to severe and often fatal IPD. In many
IRAK-4-deficient patients clinical and laboratory signs of
inflammation (such as CRP, IL-6, leukocytosis) develop
slowly even in instances of severe infection, as seen in the
first sibling in our study [31-33]. In contrast, the older sib-
ling with IRAK-4 deficiency demonstrated raised levels of
CRP (192 mg/l; normal < 5 mg/l) and IL-6 (1983 pg/ml;
normal < 7 pg/ml), potentially indicating a prolonged infec-
tion, a disease course which has also been reported in other
IRAK-4-deficient patients with severe IPD [31].
The IRAK 4 deficient patients and the patient with
SLE comprise half the fatalities in this study, potentially
confirming that immunodeficiency and autoimmune co-
morbidities influence the outcome from IPD. The other
three fatalities were due to serotypes that are covered
by PCV 7 or PCV 13 and therefore could have been
prevented.
In three patients renal failure caused by HUS was diag-
nosed. S. pneumoniae associated HUS (SP-HUS) is a ser-
ious complication of IPD associated most frequently with
pneumonia and empyema due to serotypes not included
in PCV-7, particularly serotype 3 [34]. Subsequently, SP-
HUS rates vary among different countries across the
world, depending upon vaccine type administered [34-37].
In our study three cases of HUS occurred after pneumo-
coccal vaccination had generally been recommended.
During our study period from 2001 to 2011 76% of the
patients were younger than five years of age. Splitting
this time period into pre and post vaccination era, there
is not much difference to recognise. From 2001 to 200618 children were found to be younger than five and from
2006 to 2011 24 children suffered from IPD. Most of
those patients were younger than two years, confirming
that children under the age of two are the most suscep-
tible group for the development of IPD [1,4,12]. Further,
67% of all fatalities and 33% of long term complications
occurred in this age group, emphasizing the importance
of pneumococcal vaccination and the necessity for im-
proving vaccination rates in children under two years of
age in our local area.
Even though the case numbers in our study are too
small to show representative statistics, it underlines the
clinical relevance of IPD with a significant mortality of
11%. The analysis also shows the importance of pre-
existing diseases influencing the outcome and the im-
portance of considering rare deficiencies like the IRAK 4
defect, SLE or ALPS. An important limitation of our
study was also the small numbers of identified serotypes
due to IPD reporting not being mandatory in Germany
at that time. However, information about serotypes that
could be analysed, underline the importance of the rec-
ommended pneumococcal vaccination to prevent long
term complications or death.
Overall we hypothesize that current vaccination proto-
cols in our single centre have either not been imple-
mented widely enough or that the efficacy of such
programmes are not good enough to date, to success-
fully prevent IPD. In addition, based on the detection of
a high rate of cephalosporin use as a primary treatment
line in IPD in this hospital centre, antibiotic stewardship
has been initiated formally in our hospital.
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